Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PROFITS FROM DRUGS WITH "TAINTED" ANDAs/NDAs "should be returned to the government," the National Association of Pharmaceutical Manufacturers recommended in a May 1 position statement on legislative approaches to respond to the generic drug scandal. The association maintained that profits should be returned because "neither individuals nor their employers should be allowed to profit from wrongdoing related to the FDA approval process." NAPM also said that NDAs or ANDAs that are "materially tainted" should be "withdrawn and the product recalled." Furthermore, the "recall should be at the consumer level" if the action that taints the application "affects safety of the product." Actions that would taint an NDA or ANDA include product switches during testing, fraudulent recordkeeping or submission to FDA of false or misleading information in support of an ANDA. NAPM urged that legislation to expand FDA's enforcement authority provide sanctions against innovator companies as well as generic firms. "Any legislative or regulatory response to wrongdoing should be directed at all drug activities, including NDA as well as ANDA," the association maintained. A bill being introduced by House Commerce/Oversight Subcommittee Chairman Dingell (D-Mich.) applies only to ANDAs and their sponsors; a legislative proposal by the Bush Administration applies to all industries whose products are subject to premarket review by FDA. The association supports debarment penalties imposed following due process. "Individuals who have intentionally violated the FDA process should be debarred from all FDA activities for a finite period of time," the statement asserts. "Corporations which have been found to condone wrongdoing in the approval process or have patterns of wrongdoing should be sanctioned." NAPM urged that "any sanctions or withdrawals/suspensions should be consistent with the American principles of due process and should not deprive one of its property prior to the exercise of those rights." Explaining its general support for increased penalties for actions that compromise FDA review, NAPM said, "Those engaged in illegal and unethical activities relating to the drug approval process are committing a disservice to the American public and to the great majority of manufacturers who honor and respect the public trust confided in them." The association said it "abhors those activities and feels that there is no room in our industry or our membership for those that practice them."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts